CAR T-Cell Therapy Infographic
CAR T-Cell Therapy Infographic

CAR T-Cell Therapy Overview:

Chimeric antigen receptors (CARs) are recombinant receptors for antigens which redirect the specificity and function of T lymphocytes and/or other immune cells in a single molecule. CAR T-Cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains.


CAR T-Cell Therapy Therapies: 450+


CAR T-Cell Therapy Companies: 193+ 


Key CAR T-Cell Therapy Companies

  • Alnylam Pharmaceuticals
  • JW Therapeutics
  • Gilead Sciences
  • Janssen Pharmaceuticals
  • Innovent Biologics
  • Sorrento Therapeutics
  • Cartesian Therapeutics
  • CASI Pharmaceuticals/Juventas Cell Therapy
  • Novartis
  • Poseida Therapeutics
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Sinobioway Cell Therapy Co., Ltd.
  • Tessa Therapeutics
  • Wuhan Bio-Raid Biotechnology
  • Miltenyi Biomedicine
  • Bristol-Myers Squibb
  • Autolus Limited
  • Beijing Immunochina Medical Science and Technology
  • Carsgen Therapeutics
  • Cellular Biomedicine Group
  • Chongqing Precision Biotech
  • Eureka Therapeutics
  • Formula Pharmaceuticals
  • Guangzhou Bio-gene Technology
  • Hebei Senlang Biotechnology
  • Mustang Bio
  • MolMed
  • Aurora BioPharma
  • Atara Biotherapeutics
  • Autolus
  • Bellicum Pharmaceuticals
  • Kecellitics Biotech Company Ltd
  • Yake Biotechnology
  • Minerva Biotechnologies
  • Allogene Therapeutics
  • PersonGen BioTherapeutics (Suzhou)
  • Precision BioSciences
  • Pregene (ShenZhen) Biotechnology Company
  • Shanghai GeneChem
  • Shanghai Longyao Biotechnology
  • Shenzhen BinDeBio
  • And several others.


CAR T-Cell Therapy Report Assessment

  • Company Analysis
  • Therapeutic Assessment
  • Approved/Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs


CAR T-Cell Therapy Therapeutic Assessment:

  • By Product Type
  • By Stage and Product Type
  • By Route of Administration
  • By Stage and Route of Administration
  • By Molecule Type
  • By Stage and Molecule Type


Related Reports:

  • Chimeric Antigen Receptor (CAR) T-Cell Therapy - Market Insight, Epidemiology and Market Forecast – 2032
  • CAR T-Cell Therapy for Acute Lymphoblastic Leukaemia (ALL) - Market Insight, Epidemiology And Market Forecast - 2032
  • CAR T-Cell Therapy for Multiple Myeloma - Market Insight, Epidemiology And Market Forecast - 2032
  • CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insight, Epidemiology And Market Forecast - 2032
  • CAR-T - Pipeline Insight, 2022